Day At The Track

Changes to clenbuterol testing plus!

11:18 AM 08 Apr 2020 NZST
Comment (...) Tweet Share Email Print
Canadian Pari-Mutuel Agency
Canadian Pari-Mutuel Agency

The Canadian Pari-Mutuel Agency (CPMA) announces that, effective immediately, the Elimination Guidelines have been updated and will now be ONLY AVAILABLE online.

Moving forward, the Elimination Guidelines will be updated on an "as needed" basis. For each future update, the CPMA will send out an Industry Notice to those subscribed to the Email Subscription Service.

The printed Elimination Guidelines booklet is now obsolete. Changes in this new online edition include changes to clenbuterol testing as well as the addition of five new drugs, as described below:

Guidance for clenbuterol use has been extended from 7 days to 28 days.

The new testing will be effective on May 1st, 2020.

Addition of new guidelines for the following five drugs:

Cetirizine (for example Reactine)
Clodronate (for example Osphos)
Fluticasone (for example Flovent)
Fluticasone / Salmeterol (for example Advair)
Ipratropium bromide (for example Atrovent)

The CPMA strongly recommends that you consult your veterinarian on any decision to administer any supplement or medication to a racehorse.

If you have any questions, please contact the CPMA at 1-800-268-8835 or at aafc.cpmawebacpm.aac@canada.ca.

________________________________________________________________________________________________

Addition of Altrenogest, Grapiprant, and Lubabegron to the Schedule of Prohibited Drugs in the Pari-Mutuel Betting Supervision Regulations (March 18, 2020)

In consultation with its Drug Advisory Committee, the Canadian Pari-Mutuel Agency (CPMA) has officially added the following drugs to section 1 of the Schedule to the Pari-Mutuel Betting Supervision Regulations: Altrenogest, Grapiprant and Lubabegron.

Altrenogest is an oral hormone that is used to keep female horses from coming into heat, and to suppress unwanted behaviours associated with heat cycles. It is also used to modify behaviour in male horses. Use in females is a legitimate therapeutic use. Use in males is not, and this use is prohibited by many jurisdictions internationally. In alignment with other jurisdictions, and through a policy decision, the CPMA will only prohibit this drug's use in male horses. Veterinarians and trainers may continue to use Altrenogest in female horses.

Grapiprant is a drug used to treat arthritis pain and inflammation in dogs. This drug is not recognized for use in horses.

Lubabegron is a drug used in cattle to reduce ammonia gas emissions. This drug is not recognized for use in horses.

Therefore, any detection of the above drugs, with the exception of Altrenogest in female horses, may result in a positive test.

The CPMA strongly recommends consulting a veterinarian on any decision to administer supplements or medications to a racehorse.

Testing for these drugs will begin on May 1, 2020.

 

Comment (...) Tweet Share Email Print

Read More News About...

Stallion Name

Next article: